Evaxion Biotech A/S (EVAX)
- GlobeNewswire
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for one-year clinical efficacy readout in Q3 2024 COPENHAGEN, Denmark, April 17, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces that the first patient in its EVX-01 Phase 2 trial in metastatic melanoma
- Zacks
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.
- Insider Monkey
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript April 2, 2024 Evaxion Biotech A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Christian Kanstrup: Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the […]
